NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. is a private equity fund based in Raleigh, North Carolina. According to its most recent Form D, filed Dec 28, 2015, it has sold $75,000,000 of interests to 1 investor since its first sale in Dec 2015. The minimum investment it accepts from an outside investor is $75,000,000. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Mitsuhiro Goto; NQ POF IV GP, Ltd; Ernest Brown.
- Total raised
- $75,000,000Cumulative sales reported on Form D
- Investors
- 1
- First sale
- Dec 18, 2015
- Minimum investment
- $75,000,000
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Mitsuhiro Goto; NQ POF IV GP, Ltd; Ernest Brown
- Latest Form D
- Dec 28, 2015
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Vehicles of this fund (2)
| Legal name on Form D | SEC CIK | Location reported | Total raised | Investors | Minimum | Latest Form D |
|---|---|---|---|---|---|---|
| NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. (main vehicle on this page) | 1655068 | Raleigh, North Carolina | $75,000,000 | 1 | $75,000,000 | Dec 28, 2015 |
| NovaQuest Pharma Opportunities Fund IV, L.P. | 1644216 | Raleigh, North Carolina | $0 | 0 | $0 | Jun 11, 2015 |
Funds are often offered through several legal vehicles, such as onshore, offshore, feeder, parallel or tax-exempt versions, and each one files its own Form D. These 2 filings carry the same name apart from such vehicle words or a series letter and report the same location or the same adviser, so AltMountain shows them on one page; the details above are those of NovaQuest Pharma Opportunities Fund IV (Parallel), L.P., the vehicle reporting the most raised. Each row is that vehicle's own filing, exactly as filed. The amounts should not be added together, because a feeder's money can also be counted in its master fund. Grouped by AltMountain from the filings; not confirmed by the fund. The CIK links open each vehicle's filings on SEC.gov. Source: SEC Form D filings.
Questions about NovaQuest Pharma Opportunities Fund IV (Parallel), L.P.
What is the minimum investment for NovaQuest Pharma Opportunities Fund IV (Parallel), L.P.?
According to its latest Form D, filed Dec 28, 2015, the minimum investment NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. accepts from an outside investor is $75,000,000.
Who can invest in NovaQuest Pharma Opportunities Fund IV (Parallel), L.P.?
NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. raised?
NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. reports $75,000,000 sold from 1 investor on its Form D filed Dec 28, 2015. This is cumulative sales since the offering began, not current assets or performance.
Where is NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. based?
NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. is based in Raleigh, North Carolina.
When did NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. launch?
NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. reports its first sale in Dec 2015.
Size compared with every private equity fund
Raised more than 84% of the 80 private equity funds based in North Carolina, and more than 69% of all 8,975 that report sales.